{"id":6526,"date":"2023-06-13T15:54:14","date_gmt":"2023-06-13T13:54:14","guid":{"rendered":"https:\/\/www.hartwigmedicalfoundation.nl\/?p=6526"},"modified":"2024-06-10T12:18:21","modified_gmt":"2024-06-10T10:18:21","slug":"collaboration-between-hartwig-and-ckb-makes-both-parties-stronger","status":"publish","type":"post","link":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/collaboration-between-hartwig-and-ckb-makes-both-parties-stronger\/","title":{"rendered":"Collaboration between Hartwig and CKB makes both parties stronger\u00a0"},"content":{"rendered":"\n

Hartwig Medical Foundation has worked with The Jackson Laboratory<\/a> (JAX) Clinical Knowledgebase<\/a> (CKB) team since 2020, to the benefit of both parties. For each individual patient\u2019s tumor, Hartwig detects all DNA mutations in the tumor\u2019s whole genome, while the CKB team rapidly manages information about the potential clinical relevance of oncogenic mutations. Hartwig uses that CKB information in their OncoAct report that presents the relevant molecular findings for the patient, making CKB an essential resource for interpretation of the results. Armed with the report, the patient and their practitioner can agree on a personalized treatment plan. <\/strong> <\/p>\n\n\n\n

In the field of personalized medicine and whole genome sequencing (WGS), keeping continuously up to date with the latest knowledge about treatment options is essential. However, for practitioners and medical specialists, it is often impossible to keep up with the ongoing stream of newly discovered\/published biomarker-drug combinations, and to know which of the observed DNA mutations are of clinical relevance.  Right there the collaboration of Hartwig and CKB is of great value. Paul Roepman, clinical molecular biologist in pathology at Hartwig and the Netherlands Cancer Institute gives an example: \u201cIf a novel biomarker-drug combination is published in the scientific literature during an international congress, that information becomes directly available to Hartwig from the moment it is entered into the CKB database. It can then, possibly within a week, be linked to all patients for whom Hartwig is performing WGS-based molecular diagnostics.\u201d The mutations in any tumor are unique, and while it is true that there are corresponding drivers, sometimes there are rare driver mutations for which the meaning is far less clear. \u201cWithout the detailed information provided by CKB, it is sometimes hard to recognize mutations for which a potential medicine might be is available.\u201d <\/p>\n\n\n\n

Dynamic digital source<\/strong> <\/p>\n\n\n\n

CKB is an innovative resource in which all known mutations driving cancer are reviewed the moment they are published. As such, it is a dynamic digital source for the interpretation of complete cancer genomic profiles. To scan the available literature to identify what is potentially important, CKB uses artificial intelligence (AI) technology from Microsoft. Armed with this machine assisted review, CKB\u2019s scientific experts can interpret its content, increasing the accuracy of predicting a patient\u2019s response to a combination of targeted therapies and immunotherapies, and even their resistance to specific medicines. This points the way to identifying the right mutation and the right treatment associated with it.  <\/p>\n\n\n\n

\"\"
Cara Statz, clinical analyst at JAX<\/figcaption><\/figure>\n\n\n\n

\u201cWe work with a small team of analysts and software engineers,\u201d says Cara Statz, clinical analyst at JAX. \u201cIn our database we include scientific literature that is indexed in Pubmed and clinical trials from clinicaltrials.gov. Our purpose is to be a reliable source for professionals in the oncological field. The keyword for our database is integrity. The content of the database must be accurate and up to date, making sure that it can adequately support the treatment decision in the clinical setting. There are different options to make use of the CKB database. The \u2018Core\u2019 option offers users access to all data associated with fifty genes that are generally found in cancer hotspot panels. The second, paid option is \u2018Boost\u2019. This has an advanced search function and contains more than 1,900 genes, including the fifty in \u2018Core\u2019. The third and last option \u2018Flex\u2019 offers customers the possibility to download all content and integrate it in their own workflow and reports,\u201d says Statz. <\/p>\n\n\n\n

OncoAct and ACTIN<\/strong> <\/p>\n\n\n\n

Hartwig has been using the \u2018Flex\u2019 option since 2020, making CKB an important source for the interpretation of its reports in two ways: automatic (via evidence matching\/PROTECT in OncoAct and interpretation in ACTIN) and manually via CKB\u2019s \u2018Boost\u2019 option, to which it also has access. OncoAct makes use of WGS to get a complete DNA picture of a tumor, which is compared with the \u2018normal\u2019 DNA of the patient derived from a blood sample.  <\/p>\n\n\n\n

\u201cOncoAct and ACTIN are two components connected to each other,\u201d says Paul Roepman, one of the \u2018spiders in the web\u2019 making sure that laboratory findings give clinics the essential answers they need. \u201cOncoAct is the report of the WGS findings. It is where the link with the CKB database is made. This in itself is already valuable because it helps us to interpret molecular results. But the limitation is that it is still only a DNA finding. In this respect we are sailing blind, because apart from the type of cancer we have no further information and no (treatment) background on the patient. In ACTIN, we make the link to all the information in the patient\u2019s electronic patient file, which enables us to integrate the clinical data with the molecular data and makes it possible to give the individual patient good advice about their treatment.\u201d <\/p>\n\n\n\n

Development in ACTIN<\/strong> <\/p>\n\n\n\n

At Hartwig, algorithm development lead Nina Jacobs is responsible for the development of ACTIN \u2013the Algorithmic Cancer Treatment Initiative.  <\/p>\n\n\n\n

\u201cThe ACTIN system is designed to support decision making for patients with metastasized cancer,\u201d she says. \u201cIn the algorithm we integrate clinical data, molecular data, and data about treatments \u2013 standard care and experimental \u2013 the purpose being able to map possible treatments for the patient. It is important that the clinical and molecular data are linked to the treatment data in the right and logical way, and that correct output is generated by the system\u201d.  <\/p>\n\n\n\n

\"\"
Nina Jacobs, algorithm development lead Hartwig Medical Foundation<\/figcaption><\/figure>\n\n\n\n

Paul Roepman agrees, especially where experimental treatments or studies are concerned. \u201cNow often information regarding ongoing clinical trials and\/or experimental treatment options is only available due to individual knowledge of attending medical experts,\u201d he says. \u201cIf a certain trial option isn\u2019t mentioned in a multidisciplinary meeting, for example due to the expert\u2019s absence, that possibility might be completely missed. We therefore are now testing ACTIN to objectively inform practitioners about which studies are open.\u201d <\/p>\n\n\n\n

Automated and manual<\/strong> <\/p>\n\n\n\n

The CKB data is automatically ingested into ACTIN, where it can be used to automatically annotate molecular findings. Automated annotation is performed by linking the relevant data from the CKB database on the basis of the molecular event.  <\/p>\n\n\n\n

\u201cThe purpose is to make it as easy as possible for the practitioner to see if relevant information is available in the literature, and if so, what the finding exactly is and in which article it is found,\u201d says Jacobs. \u201cThis means that the professional who receives the report doesn\u2019t have to go through all the literature to check if anything is known about the found mutation and what this could mean. It saves time and makes for an even more complete molecular image, because we have the complete literature at hand from CKB\u2019s database.\u201d <\/p>\n\n\n\n

Roepman adds: \u201cWe had already been looking at the possibilities of a knowledge database with scientific publications that could help the practitioner interpret the results of the molecular diagnostic process. With the knowledge database we initially used for this purpose \u2013 to determine whether we could find a genetic deviation that could be of use in the clinic \u2013 we eventually concluded that the information it contained did not keep up with developments. Developments in this field move so incredibly fast. That\u2019s why we decided to search for a partner with a knowledge database that could keep pace with this fast development. At that point we already knew CKB, because the academic hospitals already worked with it and considered it to be a valuable source. One of its main advantages is that it saves us a lot of manual work. That is not to say that I don\u2019t use the database manually from time to time, because I certainly do, not just at Hartwig but also in my work at AvL. This is because not every patient gets WGS.\u201d  <\/p>\n\n\n\n

About manual use of the CKB database, Jacobs says: \u201cWe indeed use it manually, to delve deeper into the database for further relevant information as a result of a certain mutation or the automatic interpretation. We then use these insights to improve the automatic interpretation if possible.\u201d <\/p>\n\n\n\n

Making the findings even better<\/strong> <\/p>\n\n\n\n

Roepman: \u201cI don\u2019t know if all practitioners understand the possibilities that CKB offers us. But I don\u2019t really know if this is even necessary. What\u2019s important to them is that they can use these possibilities to offer their patients better care. In our report they can find publications that we have used to come to our findings, which can help them sharpen their own interpretation of the data. To make it easier for them, we include hyperlinks to these publications in our reports. Based on this the practitioner can estimate whether we have, in their opinion, offered the most relevant findings or whether the patient case must be further discussed in the multidisciplinary consultation. In other words, we bring knowledge to the doctor in a more efficient and focused way.\u201d <\/p>\n\n\n\n

Roepman says his colleagues know how to make good use of the database. \u201cTheir role shifts from \u2018making their own interpretation\u2019 to \u2018evaluating if the algorithmic interpretation is correct and customized,\u201d he says, which is why he continuously tries to beat the system to make it better.  <\/p>\n\n\n\n

Further development<\/strong> <\/p>\n\n\n\n

ACTIN was initially set up for use in \u2018phase 1\u2019 departments, where it is decided whether a patient with no remaining standard treatment options could participate in an (early) clinical trial.  <\/p>\n\n\n\n

\u201cOn the basis of clinical and molecular data from the patients\u2019 health record and relevant study information \u2013 including among other things inclusion and exclusion criteria \u2013 the algorithm evaluates if a patient complies with the study criteria and if so whether a cohort in that study is open. For studies that match based on a molecular criterium, information from CKB is added about the molecular event that could be insightful,\u201d says Jacobs. <\/p>\n\n\n\n

At this point in time there are no applications other than phase 1 departments. \u201cBut we are working towards further extension towards other departments and hospitals,\u201d says Jacobs. \u201cNot just phase 1 departments in which possible participation in early-clinical studies is evaluated, but also departments where standard care is provided. If we start cooperating with teams that provide standard care, the application is still aimed at matching possible trials for the patient, for instance, phase III trials. Apart from that, we also work towards personalizing treatment proposals as much as possible, for example, by comparing the data on a patient with other comparable patients, and to collect all relevant information from the literature that is known about a treatment.\u201d  <\/p>\n\n\n\n

Roepman adds: \u201cIn my opinion helping the practitioner to make the proper match for the patient should not remain WGS specific. It should apply to all forms of molecular diagnostics.\u201d <\/p>\n\n\n\n

From client to partner<\/strong> <\/p>\n\n\n\n

Roepman says he is very satisfied with what CKB has to offer Hartwig. \u201cIt is a relatively small team,\u201d he says. \u201cCommunication lines are short, and we always get a quick response to questions.\u201d  <\/p>\n\n\n\n

Jacobs agrees. \u201cOur contact with CKB is very fluent,\u201d she says. \u201cWe speak to each other on a regular basis, for example, about the interpretation of certain molecular findings or about new literature that might be interesting for CKB to include in their database. The same applies to when we have questions about why certain literature should or should not fall inside CKB\u2019s scope of interest.\u201d <\/p>\n\n\n\n

\"Man
Paul Roepman, clinical molecular biologist in pathology Hartwig Medical Foundation<\/figcaption><\/figure>\n\n\n\n

JAX clinical analyst Statz recognizes completely what Jacobs and Roepman say. \u201cWe are very much in agreement with Hartwig\u2019s mission to use the newest technology to get the maximum result for the patient in molecular diagnostics. Just like them, we want to leave no stone unturned for the cancer patient.\u201d <\/p>\n\n\n\n

She adds that CKB is not just of interest to Hartwig, but that the same is true the other way around. \u201cAt the start, Hartwig came to us to become a client,\u201d she says. \u201cBut that was not the end of it. It has many very interesting research projects and we both concluded that this was a good basis for cooperation. We are about literature, not about the clinic. On the other hand, that is precisely the perspective that Hartwig can offer us. It provides us with knowledge about the value of our literature for the clinic. It\u2019s rather unique that a client of ours should also become a partner.\u201d <\/p>\n\n\n\n

Roepman ends with one small criticism. \u201cUsers should be aware of the fact that CKB is an American database,\u201d he says. \u201cIt only offers literature with a high level of evidence. Individual case studies do not come to light in the database because they offer insufficient evidence. Understandable of course, but it would be interesting for the European market if CKB could also make use of ESCAT next to ESMO for its selection of scientific literature. Several European parties ask for this addition.\u201d <\/p>\n\n\n\n

The subject is on CKB\u2019s radar, reacts Statz. \u201cWe are surveying the possibilities.\u201d <\/p>\n\n\n\n

More information<\/strong> <\/p>\n\n\n\n